Instructions for Rekognan (Citicoline)
English product name
Recognan
Release form
10 g/100 ml r-d/intake: park. 10 ml 5 or 10 pcs, fl 30 ml or 100 ml 1 piece with a dispensing pipette
Description Rekognan:
The solution is transparent, colorless and has a characteristic strawberry smell.
100 ml
sodium cyticoline 10.45 g,
which corresponds to the content of cyticoline 10g
Auxiliary substances: sorbitol - 20 g, glycerol - 5 g, methylparahydroxybenzoate - 0.145 mg, propyl parahydroxybenzoate - 0.025 mg, potassium sorbate - 0.3 g, sodium dihydrate citrate - 0.6 g, sodium saccharinate - 0.02 g, strawberry flavoring FRESA S.1487S - 0.04 g, citric acid - up to pH 6.0, water purified - up to 100 ml.
Release form
10 g/100 ml r-d/intake: park. 10 ml 5 or 10 pcs, fl 30 ml or 100 ml 1 piece with a dispensing pipette
Description:
The solution is transparent, colorless and has a characteristic strawberry smell.
100 ml
sodium cyticoline 10.45 g,
which corresponds to the content of cyticoline 10g
ATC codes
N06BX06 Citicoline
Clinical-pharmacological groups / Group affiliation
Nootropic preparation
Active substance
tsitikolin
Pharmacotherapy group Rekognan:
Nootropic agent
Pharmacological effect:
Nootropic agent. Citicoline, a precursor of key ultracostructural components of the cell membrane (mainly phospholipids), has a wide range of action: promotes repair of damaged cell membranes, inhibits the action of phospholipase, preventing excessive formation of free radicals, and prevents cell death by acting on the mechanisms of apoptosis.
In the acute period of stroke reduces the volume of damaged tissue, improves cholinergic transmission.
Brain injury reduces the duration of post-traumatic coma and the severity of neurological symptoms.
Citicoline improves the symptoms observed during hypoxia: memory impairment, emotional lability, lack of initiative, difficulties in performing everyday activities and self-service. It is effective in treating cognitive, sensitive and motor neurological disorders of degenerative and vascular etiology.
Method of use, course and dosage Citicoline:
When taken orally - two hundred to three hundred mg three times/day.
B/V for strokes and brain injury in acute period - one - two g/day depending on the severity of the disease for three - seven days, followed by b/m administration or ingestion.
B/m - 0.5-1 g/day
Testimony Rekognan:
- Ischemic stroke (acute);
- Ischemic and haemorrhagic stroke (recovery period);
- Traumatic brain injury (acute and recovery);
- cognitive impairment in degenerative and vascular brain diseases.
Special Instructions Citicoline
Do not use cyticoline together with drugs containing meclofenoxate.
Application in elderly patients
It can be used on indications.
Use in children Rekognan
It is contraindicated in children and adolescents under 18 years of age.
- Nosology Rekognan (ICD codes)
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- I63
- Brain infarction
- I69
- Effects of cerebrovascular disease
- S06
- Intracranial injury
- T90
- Effects of head injuries
